CSG N.V.: Record Backlog And Beaten Estimates, But The Cash Flow Gamble Keeps Me Waiting

CSG N.V. reported H1 2026 results on August 7 that, on the surface, read like a defense sector win. Revenue of €3.3 billion topped the €3.14 billion consensus estimate. Operating EBIT came in at €784 million against a €764 million forecast, with margins at 24.1% — near the top of the guided 24%–25% range. The combined backlog and pipeline reached a record €46 billion, up from €44 billion at the end of March.

The stock fell 0.48% on the results. It is down 41.4% year-to-date from its 52-week high of €35.50 and now trades around €19.26.

The disconnect between operational results and stock price is the question worth answering. I'm keeping the rating at Hold. The business is executing, but H2 cash flow hinges on a large, conditional working-capital release. If that unwind stalls, the thesis shifts fast. Until Q3 results confirm it, the risk/reward doesn't yet tip into Buy territory — even though the valuation reset has been steep.

What actually happened

Q2 revenue of €1.7 billion was in line with expectations and accounted for 43% of the full-year €7.4–7.6 billion guidance range. That puts H2 revenue target at roughly €5.7–5.9 billion, meaning CSG needs to produce about 1.7–1.8x what it delivered in Q2 over the next two quarters.

The defense systems division — CSG's core business covering ammunition and armored vehicles — delivered €2.6 billion in H1 revenue, a 27% year-over-year increase, with a 29% operating EBIT margin. Land Systems, the newer platform business, more than doubled to €445 million, now representing 46% of the order backlog. But its 17% EBIT margin is well below the defense systems average, and it dilutes the group-wide profile as its share of revenue grows.

The Ammo+ segment (commercial and small-caliber ammunition) showed the clearest recovery signal. H1 revenue was €631 million, and the EBIT margin jumped from 4% in Q1 to 11% in Q2. That's the kind of quarter-over-quarter margin repair the market needs to see, especially since the segment is exposed to copper price inflation and required two price increases.

Geographic diversification is also progressing. Ukraine's share of revenue fell to 17% from 27% at end of 2025. NATO allies outside Ukraine now account for more than half the business, and the U.S. is the second-largest market. That matters because European defense stocks took a sharp hit in April on speculation of a Ukraine peace deal, and CSG was no exception. Reducing concentration in a single volatile customer de-risks the revenue stream going forward.

The cash flow problem

Here's where the Hold rating lives.

CSG deployed €1.2 billion into net working capital in H1 2026. Net working capital rose to €2.9 billion, or 40% of revenue — double the company's own year-end target of below 20%. Management describes this build as deliberate: pre-stocking long-lead-time components and making advance payments to suppliers to support production ramp-up. Combined with higher tax payments concentrated in the first half, the result was deeply negative free cash flow.

Management says this reverses in H2. The guidance calls for a release of €1.35–1.5 billion in working capital, driven by the conversion of advance payments into delivered revenue and the completion of inventory builds. That would bring net working capital below 20% of annual revenue and push net leverage down from 1.6x to below 1.3x.

The pattern is real — CSG followed the same H1 build, H2 release cycle in 2025. And with approximately 90% of H2 defense systems revenue already under contract, delivery risk is limited. But €1.35–1.5 billion is a big number for the second half to clear. It's also the primary reason net leverage sits at 1.6x, well above the year-end target.

The stock trades at roughly €19, implying a market capitalization of about €18–19 billion on 1 billion shares outstanding. Full-year revenue guidance of €7.4–7.6 billion and EBIT margin of 24–25% implies roughly €1.8–1.9 billion in annual EBIT. That puts CSG at about 10x EBIT, which is a compressed multiple for a company growing revenue at 17% with a €46 billion backlog.

That is the cheap-enough bridge argument: the valuation has reset sharply while the operating business is expanding. If H2 cash flow follows the script — working capital unwinds, leverage drops, and free cash flow turns positive — the current price looks like the market over-penalized a seasonal cash pattern. CSG's own medium-term targets of 26–28% EBIT margin and mid-teens organic CAGR would support a meaningfully higher multiple.

But there are reasons not to rush in.

What could go wrong

Land Systems revenue doubled in H1, but the 17% margin is a drag. As this segment scales, the group-wide margin trajectory depends on whether propulsion system capacity constraints ease. Management acknowledged that demand exceeds current capacity and that certification timelines limit near-term sales. No orders have been secured yet for the new Carpa tank, which is supposed to begin production via the FNSS joint venture in Q1 2027.

The vertical integration story — new propellant, TNT, and nitroglycerin facilities in Germany, Greece, and Slovakia aimed at cutting propellant costs by roughly half — is on schedule through end of 2027. But it's a capital story, not an earnings story, for the next two quarters. Capex intensity is guided at 8.5% of revenue.

Long-range ammunition is expected to make up 60% of production by end of 2026, up from a much lower mix. These rounds take longer to produce and certify, which pushes revenue recognition into 2027. That means today's order strength doesn't necessarily translate into 2026 top-line acceleration.

And geopolitics. European defense stocks remain tethered to the Ukraine conflict and broader political risk. The April selloff on peace deal speculation showed how quickly sentiment can shift regardless of fundamentals. CSG's reduced Ukraine exposure helps, but it doesn't immunize the stock from sector-wide sentiment swings.

The catalyst clock

Q3 earnings, expected in November, are the next proof point. That quarter will tell investors whether the €1.35–1.5 billion working capital release is materializing, whether free cash flow turns positive, and whether Land Systems margins are stabilizing or still dilutive. The Iowa artillery complex and Wisconsin propulsion plant are construction milestones, not revenue events — they won't show up on the P&L until 2027.

The analyst consensus currently sits at Strong Buy with a 12-month price target averaging €29.85, implying roughly 55% upside from current levels. That's a wide spread, which tells you the sell-side sees the same opportunity I do and the same risk I'm flagging. The question is timing.

Verdict: Hold

CSG is a defense company with accelerating revenue, top-of-range margins, a record backlog, and a meaningful valuation reset. The business hasn't deteriorated — it's expanded. But the H2 cash flow story is a €1.35–1.5 billion assumption that hasn't been earned yet. The working capital cycle worked in 2025, and management has contract visibility to back the claim, but the stock doesn't deserve a Buy rating until Q3 confirms the unwind is real.

At €19, the stock is cheap relative to its backlog, margin profile, and growth trajectory. But cheap with a large conditional assumption attached is not the same as cheap and proven. I'm waiting for the November quarter to tell me whether this is a genuine risk/reward reset or just another defense name with a strong backlog and a cash flow problem.